2,3,5-trimethylhydroquinone

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Meets generally accepted scientific standards, well documented and acceptable for assessment; pre-GLP study.

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1969

Report date:

1969

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Principles of method if other than guideline:

Internal BASF method was used which was in large part equivalent to OECD guideline 401

GLP compliance:

no

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2,3,5-trimethylhydroquinone

EC Number:

211-838-3

EC Name:

2,3,5-trimethylhydroquinone

Cas Number:

700-13-0

Molecular formula:

C9H12O2

IUPAC Name:

2,3,5-trimethylbenzene-1,4-diol

Details on test material:

- Name of test material (as cited in study report): trimethylhydroquinone

Test animals

Species:

rat

Strain:

not specified

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: mean 228 g (male), 188 g (female)

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: aqueous suspension with Traganth

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 2, 16, 30%

Doses:

200, 1600, 2500, 3200, 4000, 5000, 6400 mg/kg bw

No. of animals per sex per dose:

10

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations and weighing: prior to study
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 3 200 mg/kg bw

Mortality:

6400 mg/kg bw: 10/10 males within 24 h; 10/10 females within 24 h
5000 mg/kg bw: 5/10 males within 24 h; 8/10 males within 7 days; 8/10 females within 24 h; 9/10 females within 7 days
4000 mg/kg bw: 3/10 males within 24 h; 4/10 males within 48 h; 7/10 females within 24 h; 8/10 females within 48 h
3200 mg/kg bw: 3/10 males within 24 h; 4/10 females within 24 h; 7/10 females within 48 h; 8/10 females within 7 d
2500 mg/kg bw: 3/10 males within 24 h; 3/10 females within 24 h
1600 mg/kg bw: 2/10 males within 24 h; 3/10 males within 48 h; 2/10 females within 24 h
200 mg/kg bw: no mortalities

Clinical signs:

other: Clinical symptoms: Dyspnea and prone position were the major clinical symptoms observed. 2500 - 6400 mg/kg bw: No clinical symptoms were noted immediately after dosing. At one hour after dosing, prone position, intermittent respiration, cyanosis, apa

Gross pathology:

In decedents, serous skin/mucosa with accumulation of fluid (6 rats), hydrothorax (6 rats), venous congerstion (3 rats), serous adhesion at the snout (1 rat), congestion of the liver (1 rat), chronic-inflammatory brochitis (1 rat), and bronchiectasis was observed. In surviors sacrificed after the 7-day observation, hydrothorax (2 rats) and chronic bronchitis (3 rats) was observed.